Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”

The authors regret that in the original publication Fig. 3 was incorrectly presented. The correct figure is as below.The following corrections were made:-In figure 3A, part “additional TIL parameters”, box “iTILs postTx”: The number of patients was N=82 (not N=84 as published).-In figure 3B, row “Durvalumab-arm, sTILs preTx”, column “OR”: The estimated odds ratio was 1.29 (not 1.23 as published). This correction also affects the graphical representation left to column “OR”: The diamond marker must be in the center of the line. The authors regret that in the original publication Fig. 3 was incorrectly presented. The correct figure is as below. The following corrections were made:-In figure 3A, part “additional TIL parameters”, box “iTILs postTx”: The number of patients was N=82 (not N=84 as published).-In figure 3B, row “Durvalumab-arm, sTILs preTx”, column “OR”: The estimated odds ratio was 1.29 (not 1.23 as published). This correction also affects the graphical representation left to column “OR”: The diamond marker must be in the center of the line. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyAnnals of OncologyVol. 30Issue 8PreviewCombining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NACT) in primary TNBC. Full-Text PDF Open Archive